Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$120.92 USD

120.92
356,772

+1.92 (1.61%)

Updated May 17, 2024 04:00 PM ET

After-Market: $121.01 +0.09 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

ITGR vs. GMED: Which Stock Is the Better Value Option?

ITGR vs. GMED: Which Stock Is the Better Value Option?

    ISRG or ITGR: Which is a Better Medical Instrument Stock?

    Intuitive Surgical (ISRG) and Integer Holdings' (ITGR) strong fundamentals and rising share price make them close contenders.

      3 Medical Instrument Stocks to Gain on Solid Market Prospects

      Here we take a peek at three Medical Instrument stocks that are likely to deliver strong returns in the days to come.

        ITGR vs. GMED: Which Stock Should Value Investors Buy Now?

        ITGR vs. GMED: Which Stock Is the Better Value Option?

          Integer Holdings (ITGR) Up 18.9% Since Earnings Report: Can It Continue?

          Integer Holdings (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Surmodics (SRDX) Hits Fresh Highs: Is There Still Room to Run?

            Surmodics, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for SRDX for clues.

              IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?

              IDEXX Laboratories, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for IDXX for clues.

                Integer Holdings (ITGR) Q1 Earnings Miss, View Impressive

                Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises hopes.

                  Here's Why You Should Invest in Integer Holdings Right Now

                  Integer Holdings' (ITGR) unswerving focus on customer relationship, cost reduction and burgeoning financial performance are key catalysts.

                    Here's Why You Should Invest in Stryker (SYK) Right Now

                    Stryker (SYK) gains from stellar performance of the flagship Mako platform; guidance solid.

                      Should Value Investors Pick Integer Holdings (ITGR) Stock?

                      Is Integer Holdings (ITGR) a great pick from the value investor's perspective right now? Read on to know more.

                        Integer Holdings (ITGR) Beats on Q4 Earnings, Issues '18 View

                        Integer Holdings' (ITGR) fourth-quarter 2017 results benefit from strong performance in its Medical and Non-Medical units.

                          Cardiovascular Systems' Micro Crown Now Available in Japan

                          Cardiovascular Systems (CSII) is positioned to gain from favorable trend in the CAD market.

                            Abiomed Hits New 52-Week High: 3 Factors Driving the Stock

                            Abiomed (ABMD) recently reported strong preliminary third-quarter fiscal 2018 results.

                              Becton, Dickinson Completes Enrollment in Lutonix DCB Trial

                              Becton, Dickinson's (BDX) focus in the Balloon-Angioplasty space is expected to lend the company a competitive edge in the niche MedTech markets.

                                Becton, Dickinson Hits a 52-Week High: What's Driving It?

                                Becton, Dickinson (BDX) rides on favorable regulatory developments and strategic acquisitions.

                                  5 Reasons Why McKesson Deserves a Place in Your Portfolio

                                  McKesson (MCK) continues to pursue deals, divestitures and acquisitions to drive growth. The company's impressive performance in 2017 accounts for its potential to sustain the momentum.

                                    Baxter (BAX) Launches Arisure Closed System Transfer Device

                                    Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.

                                      Integra LifeSciences Estimates Strong Revenue Figures for Q4

                                      Integra LifeSciences (IART) sees strong organic growth in the company's Specialty Surgical Solutions as well as Orthopedics and Tissue Technologies businesses.

                                        Surmodics (SRDX) Poised on Core Business Amid Forex Woes

                                        Surmodics' (SRDX) top line benefits from strong sales in Medical Device and IVD businesses. However, foreign currency is a headwind.

                                          Abaxis' (ABAX) Preliminary Results for Q3 Cheer Investors

                                          Abaxis (ABAX) expects substantial tax savings from the recent U.S. tax reform.

                                            Hill-Rom (HRC) Estimates Strong Revenue Figures for Q1

                                            Hill-Rom (HRC) expects substantial tax savings from the recent U.S. tax reform.

                                              NuVasive Q4 Preliminary Results Fail to Cheer Investors

                                              NuVasive (NUVA) continues to witness sequential growth in international revenues and expects substantial tax savings from the recent U.S. tax reform.

                                                DexCom Estimates Strong Revenue Figures for Q4 and 2017

                                                Dexcom (DXCM) to gain from strong sensor volumes, international revenues and expanding worldwide patient base in 2018.

                                                  AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2

                                                  Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.